This study shows a reduction of approximately 25% in the in vivo activity of OCT1/2 in participants with severe stages of liver fibrosis and cirrhosis after achieving sustained virologic response and highlights that OCT1/2 in vivo activity depends on the liver fibrosis stage. This evidence concerns the gene SLC22A1 and Cirrhosis.